Skip to content

Study · Observational study · 2024

3 results

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.

Barrett A, Boye KS, García-Pérez LE, Giorgino F, Guerci B, Füchtenbusch M, Yu M, Sapin H, Dib A, Heitmann E, Federici MO, Lebrec J

Journal of medical economics1 Jan 2024

PMID38963346 (opens in a new tab)DOI10.1080/13696998.2024.2367919 (opens in a new tab)PepBankPUB-38963346
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes in France, the liraglutide cohort had one of the highest mean annualized healthcare resource use costs per patient (EUR 909).

    In plain wordsIn adults with type 2 diabetes, healthcare costs per patient were among the highest in the French liraglutide group, at 909 euros a year.

    Peptide
    Liraglutide
    Outcome
    Not applicableMean annualized HCRU cost per patient, liraglutide cohort France
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Mean annualized HCRU cost
    909 €
    liraglutide cohort, France

    Source sentences

    Summary
    the highest levels were in the liraglutide cohort in France (€909)
    1 context sentence
    Summary · context
    HCRU data for cost calculations were collected by treating physicians during patient interviews at baseline and follow-up visits approximately 6, 12, 18, and 24 months after GLP-1 RA initiation with once-weekly dulaglutide or once-daily liraglutide.
  2. 02HumanObservational studyOther

    In German adults with type 2 diabetes, mean annualized healthcare resource costs were €883 per patient in the dulaglutide cohort.

    In plain wordsIn German adults with type 2 diabetes, dulaglutide treatment was linked to annual healthcare resource costs of €883 per patient.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAnnualized healthcare resource costs
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    Mean annualized HCRU costs
    883 EUR per patient
    Dulaglutide cohort in Germany

    Source sentences

    Summary
    Mean annualized HCRU costs per patient varied by treatment cohort and country: the highest levels were in the liraglutide cohort in France (€909) and the dulaglutide cohort in Germany (€883).
    2 context sentences
    Summary · context
    To describe healthcare resource utilization (HCRU) and associated costs after initiation of injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy by adult patients with type 2 diabetes (T2D) in the prospective, observational, 24-month TROPHIES study in France, Germany, and Italy.
    Summary · context
    HCRU data for cost calculations were collected by treating physicians during patient interviews at baseline and follow-up visits approximately 6, 12, 18, and 24 months after GLP-1 RA initiation with once-weekly dulaglutide or once-daily liraglutide.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneObservational studyOther

    In adults with type 2 diabetes on dulaglutide or liraglutide in three countries, medication costs were at least 60% of mean annualized costs per patient.

    In plain wordsIn adults with type 2 diabetes on two GLP-1 drugs, medicines made up at least 60% of yearly treatment costs per patient.

    Peptide
    Liraglutide
    Outcome
    Not applicableShare of mean annualized costs that was medication cost
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Medication share of annualized costs
    ≥ 60%
    dulaglutide and liraglutide cohorts pooled

    Source sentences

    Summary
    The greatest proportions (≥60%) of mean annualized costs per patient comprised medication costs.
    1 context sentence
    Summary · context
    HCRU data for cost calculations were collected by treating physicians during patient interviews at baseline and follow-up visits approximately 6, 12, 18, and 24 months after GLP-1 RA initiation with once-weekly dulaglutide or once-daily liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.